Kincell Bio, LLC signed an asset purchase agreement to acquire North Carolina manufacturing facility from Imugene Limited (ASX:IMU) for $6 million on April 16, 2024. Imugene will also transfer process and analytical development of Azer-cel to Kincell in order to support process and method optimization for commercial readiness.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.075 AUD | +7.14% | -11.76% | -31.82% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-31.82% | 339M | |
+18.23% | 47.02B | |
+48.77% | 41.86B | |
+0.69% | 41.76B | |
-4.27% | 28.8B | |
+11.69% | 26.05B | |
-21.86% | 19.15B | |
+3.60% | 12.55B | |
+28.22% | 12.34B | |
-4.57% | 11.82B |
- Stock Market
- Equities
- IMU Stock
- News Imugene Limited
- Kincell Bio, LLC signed an asset purchase agreement to acquire North Carolina manufacturing facility from Imugene Limited for $6 million.